Sialic acid and galectins mediate xenogeneic neutrophil-endothelial adhesion
Speakers: Dr. Beth French, University of Maryland
Abstract:
At Fluxion, we’re passionate about delivering cell-based solutions that facilitate the transformation of research discoveries into new ways to diagnose and treat patients. By characterizing molecular and cellular mechanisms of disease, Fluxion’s platforms help bridge the translational medicine gap, enabling rapid advances in disease research, drug discovery, and the development of diagnostic tests.
Adoptive T cell immunotherapies such as CAR-T and TCR function by reaching their targets through a complex process that can involve interactions between multiple immune cell types and the target cells, as well as interactions between the immune cells themselves.
Modeling of this process, and ensuring that the engineered T cells have the desired functional properties, requires an in vitro model that can effectively mimic the physiological conditions in the human body. To achieve this, Fluxion has developed the BioFlux "artery on a chip" systems that serve as effective platforms for these functional cell assays. These assays are designed to assess the cell trafficking process, including homing, adhesion, avidity, and transmigration, and serve as the ideal platform for functional testing of engineered T cell therapies such as CAR-T and TCR.
BioFlux runs multiple parallel experiment using high resolution image capture. Experiments can be run as time lapse or endpoint, and can quantify adhesion, transmigration, and avidity. Charts above show relative adhesion and transmigration vs. time for various CAR-T candidates.
Speakers: Dr. Beth French, University of Maryland
Abstract:
Speaker: Josephine Nalbantoglu, PhD, Associate Professor,...
Speaker: Lara Toffali, University of Verona
BeQuanti:...
Speaker: Bryan Haines, PhD, Fluxion Biosciences
BioFlux...
Speakers: Dr. You Yun and Dr. Liao Fulong, China Academy of...